A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs BGB 324 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors BerGenBio
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 18 Aug 2017 According to a BerGenBio ASA media release, the company has completed IPO and the funds from the recent IPO will enable the company to complete the four ongoing phase II trials (NCT02488408, NCT02424617, NCT03184558, NCT03184571) including this trial with read-outs expected in the second half of 2018.
- 17 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.